Department of Neurosurgery, Lenox Hill Hospital, New York, NY, 10075, USA.
Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, 11549, USA.
J Neurooncol. 2023 May;163(1):1-14. doi: 10.1007/s11060-023-04312-8. Epub 2023 Apr 22.
The phenomenon of radiation therapy (RT) causing regression of targeted lesions as well as lesions outside of the radiation field is known as the abscopal effect and is thought to be mediated by immunologic causes. This phenomena has been described following whole brain radiation (WBRT) and stereotactic radiosurgery (SRS) of brain metastasis (BM) in advanced melanoma and non-small-cell lung cancer (NSCLC). We systematically reviewed the available literature to identify which radiation modality and immunotherapy (IT) combination may elicit the abscopal effect, the optimal timing of RT and IT, and potential adverse effects inherent to the combination of RT and IT.
Using PRISMA guidelines, a search of PubMed, Medline, and Web of Science was conducted to identify studies demonstrating the abscopal effect during treatment of NSCLC or melanoma with BM.
598 cases of irradiated BM of melanoma or NSCLC in 18 studies met inclusion criteria. The most commonly administered ITs included PD-1 or CTLA-4 immune checkpoint inhibitors (ICI), with RT most commonly administered within 3 months of ICI. Synergy between ICI and RT was described in 16 studies including evidence of higher tumor response within and outside of the irradiated field. In the 12 papers (n = 232 patients) that reported objective response rate (ORR) in patients with BM treated with RT and concurrent systemic IT, the non-weighted mean ORR was 49.4%; in the 5 papers (n = 110 patients) that reported ORR for treatment with RT or IT alone, the non-weighted mean ORR was 27.8%. No studies found evidence of significantly increased toxicity in patients receiving RT and ICI.
The combination of RT and ICIs may enhance ICI efficacy and induce more durable responses via the abscopal effect in patients with brain metastases of melanoma or NSCLC.
放疗(RT)导致靶病灶和放射野外病灶消退的现象称为远隔效应,据认为是由免疫原因介导的。这种现象已在晚期黑色素瘤和非小细胞肺癌(NSCLC)的全脑放疗(WBRT)和脑转移瘤(BM)立体定向放射外科(SRS)中得到描述。我们系统地回顾了现有文献,以确定哪种放射治疗模式和免疫治疗(IT)联合可能产生远隔效应,RT 和 IT 的最佳时机,以及 RT 和 IT 联合固有潜在的不良反应。
使用 PRISMA 指南,对 PubMed、Medline 和 Web of Science 进行了搜索,以确定在治疗黑色素瘤或 NSCLC 伴 BM 时显示远隔效应的研究。
18 项研究中有 598 例黑色素瘤或 NSCLC 放射性 BM 病例符合纳入标准。最常使用的 IT 包括 PD-1 或 CTLA-4 免疫检查点抑制剂(ICI),RT 最常在 ICI 后 3 个月内进行。16 项研究描述了 ICI 和 RT 之间的协同作用,包括在照射野内和外肿瘤反应更高的证据。在 12 篇(n=232 例患者)报告了 BM 患者接受 RT 和同期全身 IT 治疗的客观缓解率(ORR)的论文中,加权平均 ORR 为 49.4%;在 5 篇(n=110 例患者)报告了 RT 或 IT 单独治疗的 ORR 的论文中,加权平均 ORR 为 27.8%。没有研究发现接受 RT 和 ICI 的患者毒性显著增加的证据。
RT 和 ICIs 的联合应用可能通过远隔效应增强 ICI 的疗效,并在黑色素瘤或 NSCLC 脑转移患者中诱导更持久的反应。